Hyperprolactinemia associated with psychotropics - A review

Human Psychopharmacology

Volumn 25, Issue 4, 2010, Pages 281-297

  Madhusoodanan, Subramoniam ^a   Parida, Suprit ^b   Jimenez, Carolina ^b  

^a St John's Episcopal Hospital   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Associated; Hyperprolactinemia; Psychotropics

Indexed keywords

ALCOHOL; AMISULPRIDE; ANTIANDROGEN; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FENFLURAMINE; HALOPERIDOL; HISTAMINE H2 RECEPTOR ANTAGONIST; HYPERTENSIVE AGENT; MOLINDONE; NEUROLEPTIC AGENT; NEUROPEPTIDE; OPIATE; OPIATE ANTAGONIST; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROLACTIN; PROTEINASE INHIBITOR; PROTIRELIN; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TIOTIXENE; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ACROMEGALY; ACTH SECRETING ADENOMA; ADENOMA; AMENORRHEA; AUTISM; AUTOREGULATION; BIPOLAR DISORDER; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COCHRANE LIBRARY; CONCENTRATION (PARAMETERS); CRANIOPHARYGIOMA; CUSHING DISEASE; DELIRIUM; DISEASE ASSOCIATION; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; EMPTY SELLA SYNDROME; ENDOCRINE DISEASE; ESTROGEN SECRETING TUMOR; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GENETIC TRANSCRIPTION; GYNECOMASTIA; HERPES ZOSTER; HORMONE INHIBITION; HORMONE SYNTHESIS; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSITIS; HYPOTHALAMUS DISEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS TUMOR; HYPOTHYROIDISM; INFORMATION RETRIEVAL; INFUNDIBULUM; LACTATION; LIVER CIRRHOSIS; LYMPHOID HYPOPHYSITIS; MASTALGIA; MEDLINE; MENSTRUAL IRREGULARITY; METASTASIS; MONITORING; NEGATIVE FEEDBACK; OVARY POLYCYSTIC DISEASE; PATIENT CARE; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTIN SECRETING CELL; PROLACTINOMA; PSEUDOPREGNANCY; RECEPTOR BINDING; REVIEW; SARCOIDOSIS; SCHIZOPHRENIA; SEIZURE; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SIGNAL TRANSDUCTION; SKULL IRRADIATION; SLEEP; SPINAL CORD INJURY; STRESS; STUTTERING; THORAX INJURY; TIC; TREATMENT INDICATION; TUBEROHYPOPHYSEAL TRACT; VASCULAR DISEASE;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; MENTAL DISORDERS; PROLACTIN; PSYCHOTROPIC DRUGS;

EID: 77953924907     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1116     Document Type: Review

References (178)

1. Abu-Fadil S, DeVane G, Siler TM, et al. Effects of oral contraceptive steroids on pituitary prolactin secretion. Contraception 1976. 13(1): 79-85.
2. Afrasiabi MA, Flomm M, Friedlander H, et al. Endocrine studies in heroin addicts. Psychoneuroendocrinology 1979. 4(2): 145-153.
3. Aguilar E, Lopez F, Pinilla L, et al. Effects of pimozide and domperidone administration on prolactin levels in neonatally estrogenized female rats. Rev Esp Fisiol 1985. 41(2): 183-186. (Pubitemid 15058720)
4. Amsterdam JD, Garcia-Espana F, Goodman D, et al. Breast enlargement during chronic antidepressant therapy. J Affect Disord 1997. 46(2): 151-156. (Pubitemid 28037487)
5. Anderson IM, Cowen PJ. Clomipramine enhances prolactin and growth hormone responses to L-tryptophan. Psychopharmacology (Berl) 1986. 89(1): 131-133.
6. Anghelescu I, Wolf J. Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. J Clin Psychiatry 2004. 65(9): 1286-1287.
7. Anton RF, Sexauer JD, Randall CL. Amoxapine elevates serum prolactin in depressed men. J Affect Disord 1983. 5(4): 305-310.
8. Apiquian R, Fresan A, Ulloa RE, et al. Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. Neuropsychopharmacology 2005. 30(12): 2236-2244. (Pubitemid 41643975)
9. Arafah BM, Nekl KE, Gold RS, et al. Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas. J Clin Endocrinol Metab 1995. 80(12): 3507-3512.
10. Ash PR, Bouma D. Exaggerated hyperprolactinemia in response to thiothixene. Arch Neurol 1981. 38(8): 534-535.
11. Atmaca M, Kuloglu M, Tezcan E, et al. Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Arch Med Res 2002. 33(6): 562-565. (Pubitemid 36026614)
12. Barbieri C, Larovere MT, Mariotti G, et al. Prolactin stimulation by intravenous labetalol is mediated inside the central nervous system. Clin Endocrinol (Oxf) 1982. 16(6): 615-619. (Pubitemid 12111432)
13. Bart G, Borg L, Schluger JH, et al. Suppressed prolactin response to dynorphin A 1-13 in methadone-maintained versus control subjects. J Pharmacol Exp Ther 2003. 306(2): 581-587.
14. Basturk M, Karaaslan F, Esel E, et al. Effects of short and long-term lithium treatment on serum prolactin levels in patients with bipolar affective disorder. Prog Neuropsychopharmacol Biol Psychiatry 2001. 25(2): 315-322. (Pubitemid 32234652)
15. Benker G, Jaspers C, Hausler G, et al. Control of prolactin secretion. Klin Wochenschr 1990. 68(23): 1157-1167.
16. Beumont P, Bruwer J, Pimstone B, et al. Brom-ergocryptine in the treatment of phenothiazine-induced galactorrhoea. Br J Psychiatry 1975. 126: 285-288.
17. Bevan JS, Burke CW, Esiri MM, et al. Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement. Am J Med 1987. 82(1): 29-32.
18. Bliesener N, Yokusoglu H, Quednow BB, et al. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report. Pharmacopsychiatry 2004. 37(4): 189-191. (Pubitemid 38916429)
19. Bonuccelli U, Murialdo G, Martino E, et al. Effects of carbamazepine on prolactin secretion in normal subjects and in epileptic subjects. Clin Neuropharmacol 1985. 8(2): 165-174.
20. Breier AF, Malhotra AK, Su TP, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999. 156(2): 294-298.
21. Bressan RA, Erlandsson K, Spencer EP, et al. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology (Berl) 2004. 175(3): 367-373. (Pubitemid 39361925)
22. Brouwers JR, Assies J, Wiersinga WM, et al. Plasma prolactin levels after acute and subchronic oral administration of domperidone and of metoclopramide: a cross-over study in healthy volunteers. Clin Endocrinol (Oxf) 1980. 12(5): 435-440.
23. Bruins Slot LA, De Vries FL, Newman-Tancredi A, et al. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol 2006. 534(1-3): 63-70.
24. Bunker MT, Marken PA, Schneiderhan ME, et al. Attenuation of antipsychotic-induced hyperprolactinemia with clozapine. J Child Adolesc Psychopharmacol 1997. 7(1): 65-69.
25. Busch DA, Fang VS, Meltzer HY. Serum prolactin levels following intramuscular chlorpromazine: two- and three-hour response as predictors of six-hour response. Psychiatry Res 1979. 1(2): 153-159.
26. Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol 2007. 21(7): 768-773.
27. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003. 166(4): 391-399.
28. Cassano GB, Fagiolini A, Lattanzi L, et al. Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy. Clin Drug Investig 2007. 27(1): 1-13.
29. Castelo-Branco C, Martinez de Osaba MJ, Fortuny A, et al. Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison. J Reprod Med 1995. 40(8): 556-560.
30. Cavallaro R, Cocchi F, Angelone SM, et al. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004. 65(2): 187-190.
31. Chan V, Wang C, Yeung RT. Effects of heroin addiction on thyrotrophin, thyroid hormones and porlactin secretion in men. Clin Endocrinol (Oxf) 1979. 10(6): 557-565.
32. Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol 2001. 11(4): 435-440.
33. Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull 2002. 36(1): 143-164.
34. Cosi C, Carilla-Durand E, Assie MB, et al. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol 2006. 535(1-3): 135-144.
35. Cowen PJ, Sargent PA. Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J Psychopharmacol 1997. 11(4): 345-348.
36. Crawford AM, Beasley CM Jr, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997. 26(1): 41-54.
37. Crowley TJ, Hydinger-Macdonald M. Motility Parkinsonism and prolactin with thiothixene and thioridazine. Arch Gen Psychiatry 1981. 38(6): 668-675.
38. Cutler AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 2003. 28(Suppl 1): 69-82.
39. David SR, Taylor CC, Kinon BJ, et al. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000. 22(9): 1085-1096.
40. De Hert M, Hanssens L, vanWinkel R, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007. 33(3): 823-830.
41. De Leo V, Lanzetta D, Vanni AL, et al. Low estrogen oral contraceptives and the hypothalamo-pituitary axis. Contraception 1991. 44(2): 155-161.
42. Delva NJ, Brooks DL, Franklin M, et al. Effects of short-term administration of valproate on serotonin-1A and dopamine receptor function in healthy human subjects. J Psychiatry Neurosci 2002. 27(6): 429-437.
43. Di Renzo G, Amoroso S, Taglialatela M, et al. Pharmacological characterization of serotonin receptors involved in the control of prolactin secretion. Eur J Pharmacol 1989. 162(2): 371-373.
44. Dorevitch A, Aronzon R, Stark M. Psychotic exacerbation attributed to low-dose bromocriptine treatment of galactorrhea and hyperprolactinemia. Acta Obstet Gynecol Scand 1991. 70(4-5): 375-376.
45. Emiliano AB, Fudge JL. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology 2004. 29(5): 833-846.
46. Fairley KF, Barrie JU, Johnson W. Sterility and testicular atrophy related to cyclophosphamide therapy. Lancet 1972. 1(7750): 568-569.
47. Foley KF, Kast RE. Review of evidence that posttransplantation psychiatric treatment commonly affects prolactin levels and thereby influences graft fate. Gen Hosp Psychiatry 2006. 28(3): 230-233.
48. Foth D, Romer T. Prolactin serum levels in postmenopausal women receiving long-term hormone replacement therapy. Gynecol Obstet Invest 1997. 44(2): 124-126.
49. Fowlie S, Burton J. Hyperprolactinaemia and nonpuerperal lactation associated with clomipramine. Scott Med J 1987. 32(2): 52.
50. Frantz AG, Prolactin N Engl J Med 1978. 298(4): 201-27.
51. Fric M, Laux G. Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics. Psychiatr Prax 2003. 30(Suppl 2): S97-101.
52. Frye PE, Pariser SF, Kim MH, et al. Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia. J Clin Psychiatry 1982. 43(6): 252-253.
53. Fujino T, Kato H, Yamashita S, et al. Effects of domperidone on serum prolactin levels in human beings. Endocrinol Jpn 1980. 27(4): 521-525.
54. Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998. 18(4): 296-304.
55. Goldstein JM. Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today (Barc) (1999a) 35(3): 193-210.
56. Goldstein SR. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health. Int J Fertil Womens Med (1999b) 44(5): 221-226.
57. Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 2002. 3(10): 1381-1391.
58. Gordon C, Whale R, Cowen PJ. Sertraline treatment does not increase plasma prolactin levels in healthy subjects. Psychopharmacology (Berl) 1998. 137(2): 201-202.
59. Goyot C, Debray Q, Hug R, et al. Measurement of basal plasma levels of 3 anterior pituitary hormones during acute or chronic treatment with tricyclic antidepressants. Encephale 1985. 11(2): 45-51.
60. Grasso A, Baraghini F, Barbieri C, et al. Endocrinological features and endometrial morphology in climacteric women receiving hormone replacement therapy. Maturitas 1982. 4(1): 19-26.
61. Haddad P, Wieck A. Antidepressant-induced hyperprolactinaemia. J Psychopharmacol 2000. 14(Suppl 3): A28.
62. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004. 64(20): 2291-314.
63. Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract 2003. 9(5): 344-353.
64. Hamner MB, Arana GW. Hyperprolactinemia in antipsychotic-treated patients: guidelines for avoidance and management. CNS Drugs 1998. 10: 209-222.
65. Hamner MB, Arvanitis LA, Miller BG, et al. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636). Psychopharmacol Bull 1996. 32(1): 107-110.
66. Henderson DC, Doraiswamy PM. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry 2008. 69(Suppl 1): 32-44.
67. Hutchinson J, Murphy M, Harries R, et al. Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors. Lancet 2000. 356(9234): 1003-1004.
68. Hwang PL, Ng CS, Cheong ST. Effect of oral contraceptives on serum prolactin: a longitudinal study in 126 normal premenopausal women. Clin Endocrinol (Oxf) 1986. 24(2): 127-133.
69. Jarvinen A, Rago L, Mannisto PT. Effects of central and peripheral type benzodiazepine ligands on thyrotropin and prolactin secretion. Neuropeptides 1992. 21(3): 183-191.
70. Josimovich JB, Lavenhar MA, Devanesan MM, et al. Heterogeneous distribution of serum prolactin values in apparently healthy young women, and the effects of oral contraceptive medication. Fertil Steril 1987. 47(5): 785-791.
71. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998. 155(7): 921-928.
72. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000. 57(6): 553-559.
73. Kauppila M, Viikari J, Irjala K, et al. The hypothalamus-pituitary-gonad axis and testicular function in male patients after treatment for haematological malignancies. J Intern Med 1998. 244(5): 411-416.
74. Kearns AE, Goff DC, Hayden DL, et al. Risperidone-associated hyperprolactinemia. Endocr Pract 2000. 6(6): 425-429.
75. Kelley SR, Kamal TJ, Molitch ME. Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia. Am J Physiol 1996. 270(1 Pt 1): E96-100.
76. Kim KS, Pae CU, Chae JH, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2002. 63(5): 408-413.
77. Kinon BJ, Basson BR, Gilmore JA, et al. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry 2000. 61(11): 833-840.
78. Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003a. 28(Suppl 2): 55-68.
79. Kinon BJ, Gilmore JA, Liu H, et al. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 2003b. 28(Suppl 2): 69-82. (Pubitemid 36332230)
80. Kinon BJ, Stauffer VL, McGuire HC, et al. The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients. J Am Med Dir Assoc 2003c. 4(4): 189-194.
81. Kinon BJ, Ahl J, Liu-Seifert H, et al. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 2006. 31(5): 577-588.
82. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999. 19(1): 57-61.
83. Klibanski A, Greenspan SL. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 1986. 315(9): 542-546. (Pubitemid 16014768)
84. Knegtering R, Baselmans P, Castelein S, et al. Predominant role of the 9-hydroxymetabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005. 162(5): 1010-1012. (Pubitemid 40676220)
85. Kolakowska T, Wiles DH, Gelder MG, et al. Clinical significance of plasma chlorpromazine levels. II. Plasma levels of the drug, some of its metabolites and prolactin in patients receiving long-term phenothiazine treatment. Psychopharmacology (Berl) 1976. 49(1): 101-107.
86. Kuhn KU, Meyer K, Maier W. Flupenthixol - a partial atypical neuroleptic?. Fortschr Neurol Psychiatr 2000. 68(Suppl 1): S38-41.
87. Kunwar AR, Megna JL. Resolution of risperidone-induced hyperprolactinemia with substitution of quetiapine. Ann Pharmacother 2003. 37(2): 206-208.
88. Laine K, Anttila M, Heinonen E, et al. Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 1997. 20(5): 419-433.
89. Lamberts SW, van Koetsveld PM, Hofland LJ. The effect of clozapine on prolactin secretion at the level of the lactotroph. Life Sci 1990. 46(14): 1013-1019.
90. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999. 20(6): 612-627.
91. Leadem CA, Yagenova SV. Effects of specific activation of mu-, delta- and kappa-opioid receptors on the secretion of luteinizing hormone and prolactin in the ovariectomized rat. Neuroendocrinology 1987. 45(2): 109-117.
92. Lee PA, Kelly MR, Wallin JD. Increased prolactin levels during reserpine treatment of hypertensive patients. JAMA 1976. 235(21): 2316-2317.
93. Lee MA, Bowers MM, Nash JF, et al. Neuroendocrine measures of dopaminergic function in chronic cocaine users. Psychiatry Res 1990. 33(2): 151-159.
94. Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2006. 30(4): 714-717.
95. Luciano AA, Sherman BM, Chapler FK, et al. Hyperprolactinemia and contraception: a prospective study. Obstet Gynecol 1985. 65(4): 506-510.
96. Madhusoodanan S, Moise D, Pathak R. Hyperprolactinemia associated with risperidone a brief review. Helix review series 2007. 15-19.
97. Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002. 63(Suppl 4): 56-62.
98. Mannisto PT, Korttila K, Seppala T. Serum prolactin levels after a single and subchronic oral administration of chlorpromazine and sulpiride. A cross-over study in healthy volunteers. Arzneimittelforschung 1978. 28(1): 76-78.
99. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004. 161(8): 1334-1349.
100. Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992. 11(10): 851-856.
101. Markianos M, Hatzimanolis J, Lykouras L, et al. Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine. Schizophr Res 2002. 56(1-2): 11-17.
102. Maskall DD, Zis AP, Lam RW, et al. Prolactin response to buspirone challenge in the presence of dopaminergic blockade. Biol Psychiatry 1995. 38(4): 235-239.
103. Matsuoka I, Nakai T, Miyake M, et al. Effects of bromocriptine on neuroleptic-induced amenorrhea, galactorrhea and impotence. Jpn J Psychiatry Neurol 1986. 40(4): 639-646.
104. McCance SL, Cohen PR, Cowen PJ. Lithium increases 5-HT-mediated prolactin release. Psychopharmacology (Berl) 1989. 99(2): 276-281.
105. McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 2004. 18(13): 933-956. (Pubitemid 39612020)
106. Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 2005. 66(6): 761-767.
107. Meltzer HY, Fang VS. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976. 33(3): 279-286.
108. Meltzer HY, Gudelsky GA. Dopaminergic and serotonergic effects of clozapine. Implications for a unique clinical profile. Arzneimittelforschung 1992. 42(2A): 268-272.
109. Meltzer HY, Maes M. Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjects. Biol Psychiatry 1994. 35(5): 316-323.
110. Meltzer HY, Fang VS, Tricou BJ, et al. Effect of antidepressants on neuroendocrine axis in humans. Adv Biochem Psychopharmacol 1982. 32: 303-316.
111. Meltzer HY, Busch DA, Fang VS. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res 1983. 9(4): 271-283.
112. Mendelson JH, Mello NK, Teoh SK, et al. Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones. J Clin Endocrinol Metab 1989. 69(6): 1256-1260.
113. Miller KK. Management of hyperprolactinemia in patients receiving antipsychotics. CNS Spectr 2004. 9(8 Suppl 7): 28-32.
114. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005. 80(8): 1050-1057.
115. Molitch ME. Drugs and prolactin. Pituitary 2008. 11(2): 209-218.
116. Molitch ME, Reichlin SI. Hypothalamic hyperprolactinemia: neuroendocrine regulation of prolactin secretion in patients with lesions of the hypothalamus and pituitary stalk. In Prolactin: Basic and Clinical Correlates. RM, MacLeod MO, Thorner U Scapagnini (eds). Liviana Press: Singapore, 1985.
117. Monteleone P, Zontini G, Steardo L. Failure of the GABAergic drug, sodium valproate, to reduce basal plasma prolactin secretion in chronic schizophrenia. Psychoneuroendocrinology 1985. 10(4): 475-80.
118. Montgomery J, Winterbottom E, Jessani M, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 2004. 65(11): 1491-1498.
119. Muck-Seler D, Pivac N, Sagud M, et al. The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2002. 26(7-8): 1235-1243.
120. Muller EE, Locatelli V, Cella S, et al. Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications. Drugs 1983. 25(4): 399-432.
121. Naidich MJ, Russell EJ. Current approaches to imaging of the sellar region and pituitary. Endocrinol Metab Clin North Am 1999. 28(1): 45-79, vi.
122. Newman ME, Shapira B, Lerer B. Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: a critical review. Int J Neuropsychopharmacol 1998. 1(1): 49-69.
123. Nielsen JL. Plasma prolactin during treatment with nortriptyline. Neuropsychobiology 1980. 6(1): 52-55.
124. Nutt D, Middleton H, Franklin M. The neuroendocrine effects of oral imipramine. Psychoneuroendocrinology 1987. 12(5): 367-375.
125. Otani K, Yasui N, Kaneko S, et al. Trazodone treatment increases plasma prolactin concentrations in depressed patients. Int Clin Psychopharmacol 1995. 10(2): 115-117.
126. Pandurangi AK, Narasimhachari N, Blackard WG, et al. Relation of serum molindone levels to serum prolactin levels and antipsychotic response. J Clin Psychiatry 1989. 50(10): 379-381. (Pubitemid 19267918)
127. Panerai AE, Petraglia F, Sacerdote P, et al. Mainly mu-opiate receptors are involved in luteinizing hormone and prolactin secretion. Endocrinology 1985. 117(3): 1096-1099. (Pubitemid 15020036)
128. Paparrigopoulos T, Liappas J, Tzavellas E, et al. Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 2007. 31(1): 92-96. (Pubitemid 44959254)
129. Perrone G, Falaschi P, Capri O, et al. Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women. Int J Fertil Menopausal Stud 1994. 39(4): 202-207.
130. Peterson MC. Reversible galactorrhea and prolactin elevation related to fluoxetine use. Mayo Clin Proc 2001. 76(2): 215-216.
131. Petit A, Piednoir D, Germain ML, et al. Drug-induced hyperprolactinemia: a case-non-case study from the national pharmacovigilance database. Therapie 2003. 58(2): 159-163.
132. Pfeiffer A, Braun S, Mann K, et al. Anterior pituitary hormone responses to a kappa-opioid agonist in man. J Clin Endocrinol Metab 1986. 62(1): 181-185.
133. Polleri A, Masturzo P, Murialdo G, et al. Dose and sex related effects of aromatic aminoacids decarboxylase inhibitors on serum prolactin in humans. Acta Endocrinol (Copenh) 1980. 93(1): 7-12.
134. Porter RJ, McAllister-Williams RH, Young AH. Acute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers. Psychopharmacology (Berl) 1999. 146(2): 194-198.
135. Price LH, Charney DS, Heninger GR. Effects of tranylcypromine treatment on neuroendocrine, behavioral, and autonomic responses to tryptophan in depressed patients. Life Sci 1985. 37(9): 809-818.
136. Price LH, Charney DS, Delgado PL, et al. Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan. Serotonergic function and the mechanism of antidepressant action. Arch Gen Psychiatry 1989. 46(7): 625-631.
137. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000. 57(3): 249-258.
138. Reyniak JV, Wenof M, Aubert JM, et al. Incidence of hyperprolactinemia during oral contraceptive therapy. Obstet Gynecol 1980. 55(1): 8-11.
139. Risch SC, Janowsky DS, Siever LJ, et al. Correlated cholinomimetic- stimulated beta-endorphin and prolactin release in humans. Peptides 1982. 3(3): 319-322.
140. Rivera JL, Lal S, Ettigi P, et al. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 1976. 5(3): 273-282.
141. Rolandi E, Magnani G, Milesi GM, et al. Effect of a psychoactive drug, trazodone, on prolactin secretion in man. Neuropsychobiology 1981. 7(1): 17-19.
142. Rossi L, Bonuccelli U, Marcacci G, et al. Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports. Ital J Neurol Sci 1983. 4(2): 207-210.
143. Sachar EJ, Gruen PH, Karasu TB, et al. Thioridazine stimulates prolactin secretion in man. Arch Gen Psychiatry 1975. 32(7): 885-886.
144. Schlegel W, Petersdorf LI, Junker R, et al. The effects of six months of treatment with a low-dose of conjugated oestrogens in menopausal women. Clin Endocrinol (Oxf) 1999. 51(5): 643-651.
145. Schlienger JL, Kapfer MT, Singer L, et al. Different effects of tricyclic (clomipramine and amitriptyline) and tetracyclic (maprotiline) antidepressors on the release of thyroid stimulating hormone, prolactin and growth hormone to thyrostimulating releasing hormone in patients with psychoaffective disorders (author's transl). Acta Psychiatr Belg 1980. 80(5): 584-599.
146. Schlosser R, Grunder G, Anghelescu I, et al. Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 2002. 46(1): 33-40.
147. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002. 47(1): 27-38.
148. Seppala T, Ranta T, Shrotriya RC. Serum prolactin levels after buspirone in man. Med Biol 1987. 65(1): 61-63.
149. Shamberger RC, Rosenberg SA, Seipp CA, et al. Effects of high-dose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma. Cancer Treat Rep 1981. 65(9-10): 739-746.
150. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003. 28(8): 1400-1411.
151. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007. 164(9): 1404-1410.
152. Shin SH, Obonsawin MC, Van Vugt DA, et al. Morphine can stimulate prolactin release independent of a dopaminergic mechanism. Can J Physiol Pharmacol 1988. 66(11): 1381-1385.
153. Shlik J, Aluoja A, Vasar V, et al. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 1997. 22(5): 332-340.
154. Slater SL, Lipper S, Shiling DJ, et al. Elevation of plasma-prolactin by monoamine-oxidase inhibitors. Lancet 1977. 2(8032): 275-276.
155. Smith S. Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? J Reprod Med 1992. 37(8): 737-740.
156. Smith S, Wheeler MJ, Murray R, et al. The effects of antipsychotic- induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 2002. 22(2): 109-114.
157. Spigset O, Mjorndal T. The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status. J Clin Psychopharmacol 1997. 17(4): 292-297.
158. Spitzer M, Sajjad R, Benjamin F. Pattern of development of hyperprolactinemia after initiation of haloperidol therapy. Obstet Gynecol 1998. 91(5 Pt 1): 693-695.
159. Steiner J, Cassar J, Mashiter K, et al. Effects of methyldopa on prolactin and growth hormone. Br Med J 1976. 1(6019): 1186-1188.
160. Stevens JR, Kymissis PI, Baker AJ. Elevated prolactin levels in male youths treated with risperidone and quetiapine. J Child Adolesc Psychopharmacol 2005. 15(6): 893-900.
161. Street J, Kinon B, Stauffer V. et al. Olanzapine in dementia. In Olanzapine (Zyprexa®): a novel antipsychotic Lippincott. P, Tran F, Bysmester N Tye (Eds.) Williams and Wilkins Healthcare: London, 2000.
162. Takahashi H, Higuchi H, Kamata M, et al. Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea. J Neuropsychiatry Clin Neurosci 2003. 15(3): 375-7.
163. Tamagna EI, Lane W, Hershman JM, et al. Effect of chronic metoclopramide therapy on serum pituitary hormone concentrations. Horm Res 1979. 11(4): 161-169.
164. Tolis G, Hickey J, Guyda H. Effects of morphine on serum growth hormone, cortisol, prolactin and thyroid stimulating hormone in man. J Clin Endocrinol Metab 1975. 41(4): 797-800.
165. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997. 154(4): 457-465.
166. Tollin SR. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 2000. 23(11): 765-770.
167. Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag 2007. 3(5): 929-951.
168. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997. 17(5): 407-418.
169. Turrone P, Kapur S, Seeman MV, et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002. 159(1): 133-135.
170. Urban RJ, Veldhuis JD. A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women. Am J Obstet Gynecol 1991. 164(1 Pt 1). 147-152.
171. Van Vugt DA, Meites J. Influence of endogenous opiates on anterior pituitary function. Fed Proc 1980. 39(8): 2533-2538.
172. von Bardeleben U, Benkert O, Holsboer F. Clinical and neuroendocrine effects of zotepine-a new neuroleptic drug. Pharmacopsychiatry 1987. 20(1 Spec No). 28-34.
173. Wahl R, Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry 2005. 162(8): 1542-1543.
174. Walsh AE, Cowen PJ. Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment. J Clin Psychopharmacol 1994. 14(4): 268-273.
175. Whiteman PD, Peck AW, Fowle AS, et al. Failure of bupropion to affect prolactin or growth hormone in man. J Clin Psychiatry 1983. 44(5 Pt 2). 209-210.
176. Wieck A, Haddad P. Hyperprolactinaemia caused by antipsychotic drugs. BMJ 2002. 324(7332): 250-252.
177. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003. 182: 199-204.
178. Zis AP, Haskett RF, Albala AA, et al. Morphine inhibits cortisol and stimulates prolactin secretion in man. Psychoneuroendocrinology 1984. 9(4): 423-427.